Cargando…

Supply and delivery of vaccines for global health

Vaccines developed in high-income countries have been enormously successful in reducing the global burden of infectious diseases, saving perhaps 2.5 million lives per year, but even for successful cases, like the rotavirus vaccine, global implementation may take a decade or more. For unincentivized...

Descripción completa

Detalles Bibliográficos
Autores principales: Excler, Jean-Louis, Privor-Dumm, Lois, Kim, Jerome H
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Published by Elsevier Ltd. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8035049/
https://www.ncbi.nlm.nih.gov/pubmed/33845349
http://dx.doi.org/10.1016/j.coi.2021.03.009
_version_ 1783676647769112576
author Excler, Jean-Louis
Privor-Dumm, Lois
Kim, Jerome H
author_facet Excler, Jean-Louis
Privor-Dumm, Lois
Kim, Jerome H
author_sort Excler, Jean-Louis
collection PubMed
description Vaccines developed in high-income countries have been enormously successful in reducing the global burden of infectious diseases, saving perhaps 2.5 million lives per year, but even for successful cases, like the rotavirus vaccine, global implementation may take a decade or more. For unincentivized vaccines, the delays are even more profound, as both the supply of a vaccine from developing country manufacturers and vaccine demand from countries with the high disease burdens have to be generated in order for impact to be manifest. A number of poverty-associated infectious diseases, whose burden is greatest in low-income and middle-income countries, would benefit from appropriate levels of support for vaccine development such as Group A Streptococcus, invasive non-typhoid salmonella, schistosomiasis, shigella, to name a few. With COVID-19 vaccines we will hopefully be able to provide novel vaccine technology to all countries through a unique collaborative effort, the COVAX facility, led by the World Health Organization (WHO), Gavi, and the Coalition for Epidemic Preparedness Innovations (CEPI). Whether this effort can deliver vaccine to all its participating countries remains to be seen, but this ambitious effort to develop, manufacture, distribute, and vaccinate 60–80% of the world’s population will hopefully be a lasting legacy of COVID-19.
format Online
Article
Text
id pubmed-8035049
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Published by Elsevier Ltd.
record_format MEDLINE/PubMed
spelling pubmed-80350492021-04-12 Supply and delivery of vaccines for global health Excler, Jean-Louis Privor-Dumm, Lois Kim, Jerome H Curr Opin Immunol Article Vaccines developed in high-income countries have been enormously successful in reducing the global burden of infectious diseases, saving perhaps 2.5 million lives per year, but even for successful cases, like the rotavirus vaccine, global implementation may take a decade or more. For unincentivized vaccines, the delays are even more profound, as both the supply of a vaccine from developing country manufacturers and vaccine demand from countries with the high disease burdens have to be generated in order for impact to be manifest. A number of poverty-associated infectious diseases, whose burden is greatest in low-income and middle-income countries, would benefit from appropriate levels of support for vaccine development such as Group A Streptococcus, invasive non-typhoid salmonella, schistosomiasis, shigella, to name a few. With COVID-19 vaccines we will hopefully be able to provide novel vaccine technology to all countries through a unique collaborative effort, the COVAX facility, led by the World Health Organization (WHO), Gavi, and the Coalition for Epidemic Preparedness Innovations (CEPI). Whether this effort can deliver vaccine to all its participating countries remains to be seen, but this ambitious effort to develop, manufacture, distribute, and vaccinate 60–80% of the world’s population will hopefully be a lasting legacy of COVID-19. Published by Elsevier Ltd. 2021-08 2021-04-10 /pmc/articles/PMC8035049/ /pubmed/33845349 http://dx.doi.org/10.1016/j.coi.2021.03.009 Text en © 2021 Published by Elsevier Ltd. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Excler, Jean-Louis
Privor-Dumm, Lois
Kim, Jerome H
Supply and delivery of vaccines for global health
title Supply and delivery of vaccines for global health
title_full Supply and delivery of vaccines for global health
title_fullStr Supply and delivery of vaccines for global health
title_full_unstemmed Supply and delivery of vaccines for global health
title_short Supply and delivery of vaccines for global health
title_sort supply and delivery of vaccines for global health
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8035049/
https://www.ncbi.nlm.nih.gov/pubmed/33845349
http://dx.doi.org/10.1016/j.coi.2021.03.009
work_keys_str_mv AT exclerjeanlouis supplyanddeliveryofvaccinesforglobalhealth
AT privordummlois supplyanddeliveryofvaccinesforglobalhealth
AT kimjeromeh supplyanddeliveryofvaccinesforglobalhealth